ArticleJACC. Case reports2026
Role of Finerenone in Duchenne Muscular Dystrophy in a 45-Year-Old Man: Outcome and Brief Review.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuchenne muscular dystrophy (DMD) is an X-linked neuromuscular disorder characterized by the absence of dystrophin, leading to progressive skeletal and cardiac muscle degeneration. Cardiomyopathy is a leading cause of morbidity and mortality in patients with DMD, often manifesting as a dilated cardiomyopathy with myocardial fibrosis and arrhythmia. Mineralocorticoid receptor antagonists, including the nonsteroidal agent finerenone, have emerged as disease-modifying therapies because of their antifibrotic, anti-inflammatory, and cardioprotective properties. CASE SUMMARY: A 45-year-old man with DMD and progressive nonischemic cardiomyopathy was initiated on finerenone in addition to guideline-directed medical therapy. Over 16 months, he demonstrated improvement in left ventricular ejection fraction and ventricular remodeling without adverse effects. DISCUSSION: Finerenone is a nonsteroidal mineralocorticoid receptor antagonist with potent antifibrotic and anti-inflammatory properties. This case highlights its potential role in DMD cardiomyopathy, where fibrosis is central to disease progression. TAKE-HOME MESSAGE: Finerenone may represent a novel therapy in DMD-associated cardiomyopathy and warrants further investigation for use in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.